Insider · CIK 0001678736

Poukalov Konstantin

Reports to the SEC for 8 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001678736

Forms 4 and 5

Insider transactions

26 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-06-13	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director	AAward	+30K sh	—	—	30,000
2024-02-15	LIANYLianBioF Tax Payment	Director	FTax Payment	−19.2K sh	$4.76	−$91.5K	17,082
2024-02-15	LIANYLianBio · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−36.3K sh	—	—	0
2024-02-15	LIANYLianBioM Exercise/Conversion	Director	MExercise/Conversion	+36.3K sh	$2.52	+$91.5K	36,300
2023-06-30	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director	AAward	+20K sh	—	—	20,000
2023-06-21	LIANYLianBio · Stock Option (Right to Buy)A Award	Director	AAward	+36.3K sh	—	—	36,300
2022-06-23	LIANYLianBio · Stock Option (Right to Buy)A Award	Director	AAward	+36.3K sh	—	—	36,300
2022-06-16	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director	AAward	+7,250 sh	—	—	7,250
2021-05-26	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director	AAward	+7,250 sh	—	—	7,250
2021-02-09	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+64.7K sh	$13.80	+$893K	14,834,964
2021-02-09	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+35K sh	$14.60	+$510K	14,869,915
2021-02-08	Landos Biopharma, Inc.C Conversion	Director, 10% Owner	CConversion	+13.4M sh	—	—	13,369,728
2021-02-08	Landos Biopharma, Inc.Series B Preferred StockC Conversion	Director, 10% Owner	CConversion	−7.49M sh	—	—	0
2021-02-08	Landos Biopharma, Inc.Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−5.88M sh	—	—	0
2021-02-08	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+1.25M sh	$16.00	+$20M	14,619,728
2021-02-08	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+34.6K sh	$11.38	+$394K	14,681,792
2021-02-08	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+86.7K sh	$12.53	+$1.09M	14,768,463
2021-02-08	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+1,771 sh	$13.10	+$23.2K	14,770,234
2021-02-05	Landos Biopharma, Inc.P Purchase	Director, 10% Owner	PPurchase	+27.5K sh	$11.14	+$306K	14,647,181
2020-04-30	LYRALyra Therapeutics, Inc. · Stock OptionA Award	Director	AAward	+14.5K sh	—	—	14,500
2017-12-08	Kadmon Holdings, Inc.Stock Appreciation RightA Award	Executive Vice President, CFO	AAward	+205K sh	—	—	205,000
2016-12-15	Kadmon Holdings, Inc.Stock Option (right to buy)A Award	Executive Vice President, CFO	AAward	+350K sh	$4.66	+$1.63M	350,000
2016-11-11	Kadmon Holdings, Inc.P Purchase	Executive Vice President, CFO	PPurchase	+1,000 sh	$5.43	+$5,430	4,000
2016-11-11	Kadmon Holdings, Inc.P Purchase	Executive Vice President, CFO	PPurchase	+1,000 sh	$5.95	+$5,950	3,000
2016-11-11	Kadmon Holdings, Inc.P Purchase	Executive Vice President, CFO	PPurchase	+1,000 sh	$5.96	+$5,960	1,000
2016-11-11	Kadmon Holdings, Inc.P Purchase	Executive Vice President, CFO	PPurchase	+1,000 sh	$5.91	+$5,910	2,000

Recent filings

Accepted (ET)
Jun 144
Poukalov Konstantin0000950170-24-073650
SEC(opens sec.gov)
Feb 204
Poukalov Konstantin0001062993-24-003733
SEC(opens sec.gov)
Jul 54
Poukalov Konstantin0000950170-23-031869
SEC(opens sec.gov)
Jun 234
Poukalov Konstantin0001062993-23-013980
SEC(opens sec.gov)
Jun 274
Poukalov Konstantin0001062993-22-015490
SEC(opens sec.gov)
Jun 214
Poukalov Konstantin0000899243-22-023337
SEC(opens sec.gov)
May 284
Poukalov Konstantin0000899243-21-021189
SEC(opens sec.gov)
Feb 94
Poukalov Konstantin0001209191-21-009047
SEC(opens sec.gov)
Feb 84
Poukalov Konstantin0001209191-21-008587
SEC(opens sec.gov)
May 14
Poukalov Konstantin0000899243-20-011751
SEC(opens sec.gov)

Companies

Address

C/O KADMON HOLDINGS, INC. 450 E 29TH STREET

NEW YORK, NY, 10016